CDK-IN-2

CDK-IN-2 is a small molecule inhibitor of cyclin-dependent kinases (CDKs) frequently utilized in high-throughput ex vivo drug sensitivity screening panels. In the context of relapsed/refractory acute myeloid leukemia (R/R AML), CDK-IN-2 has demonstrated significant potency, with studies showing high sensitivity in a vast majority of patient-derived samples. While it is often categorized alongside investigational anti-cancer drugs in functional precision medicine platforms, it is primarily a research-grade compound used to identify biological signatures of drug response and to probe the therapeutic potential of targeting cell cycle and transcriptional regulators. Its mechanism involves the potent inhibition of various CDK isoforms, which are critical for the proliferation and survival of malignant cells.

Other names

CDK Inhibitor 2CDK Inhibitor IICDK-IN-II